NasdaqCM:CELCBiotechs
Should Celcuity’s $500 Million Convertible Notes and VIKTORIA-1 Data Shift the CELC Investment Thesis Require Action From Celcuity (CELC) Investors?
Earlier this month, Celcuity Inc. priced an upsized US$500,000,000 offering of 0.250% convertible senior notes due 2032 and outlined plans to use the proceeds to repay existing debt and fund working capital, clinical development, potential commercialization and possible future acquisitions.
In parallel, Celcuity reported detailed Phase 3 VIKTORIA-1 data showing gedatolisib-based regimens improved progression-free outcomes versus alpelisib plus fulvestrant in PIK3CA mutant advanced breast...